PharmaDiagnostics, a developer of label-free screening technology that does not require specialised instrumentation, has appointed Dr Sylviane Boucharens as director of assay development. She joins from Merck’s MSD site in Newhouse, Scotland, where she was head of global compound repository and in vitro screening.
Boucharens will play a central role in driving the growth of PharmaDiagnostics’ assay product range, and in developing business globally. She worked at Merck from 2000 to 2011. She started her career in the pharmaceutical industry in 1995 when she joined the Immunology Department in the Laboratoires Fournier (Dijon, France).
PharmaDiagnostics appoints director of assay development
Former pharma department head joins Belgian firm
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Scaling complexity without losing control: how manufacturing processes are adapting to the next generation of medicines (part V)
As therapies grow more complex, manufacturers must build commercial-scale thinking into early development, focus on meaningful monitoring and favour simplicity to keep production predictable
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Scaling complexity without losing control: how manufacturing processes are adapting to the next generation of medicines (part IV)
Real-time monitoring, digital-first platforms and early scalability planning can help manufacturers to maintain quality, flexibility and speed as dosage forms become more sophisticated
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Scaling complexity without losing control: how manufacturing processes are adapting to the next generation of medicines (part III)
Early collaboration, specialist purification and carefully targeted investment help manufacturers to bridge development and commercial production, improving process robustness, efficiency and dependable supply